Login to Your Account



Ablynx's nanobody approach successful in phase II TTP trial

By Nuala Moran
Staff Writer

Tuesday, June 17, 2014
LONDON – Ablynx NV's caplacizumab is in line to be the first drug for treating rare blood coagulation disorder acquired thrombotic thrombocytopenic purpura (TTP), after the company reported positive phase II results.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription